Executive Summary
Angel Biotechnology Holdings PLC (LON:ABH) is a UK-based biopharmaceutical company that is listed on the AIM. The company manufactures recombinant proteins, cellular therapies and stem cells, virus medication and antibodies. In 2009, Angel Biotechnology earned revenue of £1.5m and it made an operating loss of £754,000. The company's core competencies are in fermentation and protein purification using microbial and animal cell culture to produce active biomolecules for use in medicines and vaccines.
Company History
Current Events
Business Model
Angel Biotechnology is a world class, contract biomanufacturing company offering process development services and pre-GMP and cGMP manufacturing to support biotechnology and pharmaceutical companies worldwide. With expertise in the manufacture and development of recombinant proteins, cellular therapies and stem cells, antibodies, and viruses, Angel is able to provide development and manufacturing support for production of biologics working from laboratory scale to development of a robust manufacturing process. These services range from strain development, through near GMP manufacture of the small quantities needed for pre-clinical studies to the high quality, cGMP production needed for clinical trials and beyond. [1]
Products/Services
Angel's principal activity is the manufacture and supply of materials for use in early stage drug development and pre-clinical studies, along with drug product and CMC documentation for Phases I, II and III clinical trials and the manufacture of licensed drugs or vaccines.
Segments/Customers
Production/Operations
Angel operates out of two sites, at Cramlington near Newcastle upon Tyne and at Pentlands Science Park near Edinburgh. Certification of its Pentlands facility by the MHRA to the EU Clinical Trials Regulations as cGMP compliant has been granted. Certification of its Cramlington facility is expected to be applied for and completed by the first quarter of 2006. The Group currently employs a staff of 32 people (excluding Directors), of whom a third hold doctorates.
Distribution/Routes to Market
Market & Competition
Market Share
The global biopharmaceuticals contract manufacturing industry was expected to reach US$2 billion in 2005. Angel will bene¢t from the following industry trends:
- The use by biotechnology companies of CMOs to manufacture biologics that require specialised resources and skills;
- The requirement that companies developing human drug products must comply with the Clinical Trials Regulations;
- The shift in drug discovery from large pharmaceutical companies to SMEs, which prefer to target smaller CMOs for reasons of £exibility, responsiveness and quality at best cost; and the overall growth of the…
